Study Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
Want to learn more about this trial?
Request More InfoInterventions
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cellsBIOLOGICAL
Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Zhujiang Hospital of Southern Medical University | Guangzhou | Guangdong | China |
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |
| Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center | Kunming | Yunnan | China |